Hans Balz – Managing Director – MBA Marketing & PR BioPharma Research & Development

He has many years of experience in the international pharmaceutical industry as a certified pharmaceutical clinical representative for human and veterinary medicine (antibiotics, antirheumatics, anti-inflammatories, analgesics, anesthesiology, rheology, ophthalmology, nutritional science, etc.) and a licensed stockbroker on various international stock exchanges in Düsseldorf, Berlin, Rotterdam, Basel, Brussels, London, and Denver. For decades, he served as a PR manager, sales director, and managing director for various international pharmaceutical companies, as well as the owner of a multi-year "hyperbaric ozone" medical technology distribution company. For several years, he has been working as a director and principal shareholder of a globally operating biopharmaceutical R&D corporation, independently and without an employee in Switzerland, Austria, Tbilisi/Georgia, and the USA. Previously, he served as a clinical representative for hospitals throughout Germany. Hans Balz, along with his entire family – wife and two daughters with their families, his boxer Alma, two other male dogs, and a small cat from the organization "A Heart for Boxers & Animals" – is a long-time, dedicated environmental activist (with his family) involved with Sea Shepherd and Greenpeace. He now supports the newly founded "Paul Watson Foundation Germany e.V.," among other things, for the rescue and planned support of a new orca foundation.* In addition to his personal goal of introducing bacteriophages for use against deadly hospital killers like MRSA and other lethal infections to the international pharmaceutical market as quickly as possible, he pursues another important private goal: the rescue of birds and rodents of all kinds, including pigeons and other rodent species, as well as the Jane Goodall Foundation (A Life for Monkeys).

*Our main goal for the coming years!

Besides Hans Balz's personal goal and that of his research team, bacteriophages for use against deadly hospital killers To introduce MRSA and other deadly infections to the international, global pharmaceutical market as quickly as possible, it is crucial to successfully complete the clinical trials already underway and bring them to the end of clinical phase III/IV. This is because multi-resistant germs could cause over 10 million deaths annually, with an estimated annual increase by 2050 at the latest, unless he and his R&D team tirelessly and successfully achieve their long-standing goal with Phage-Olympic Therapeutics research and development. He and his R&D team remain firmly convinced of this, as the signs of the times for bacteriophages vs. MRSA are extremely positive…!